At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 19 enrolled
Drug / intervention
Itacitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib Study of Itacitinib, a JAK1 Inhibitor, in Advanced Hepatocellular Carcinoma
In Brief
A Phase 1 clinical trial evaluating Itacitinib for Advanced Hepatocellular Carcinoma. Completed, enrolled 19 participants across 1 site.
Detailed Summary
This research will assess the effects of Itacitinib as a second line treatment for patients with advanced inflammatory hepatocellular carcinoma (HCC), a type of liver cancer. Itacinib is a protein inhibitor of the tyrosine kinase, JAK1, which is believed to enable cancer cells to metastasise to other parts of the body.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Hepatocellular Carcinoma
CountriesUnited Kingdom
CollaboratorsIncyte Biosciences UK
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedApr 2020
Primary CompletionApr 2023
TodayJul 2026
First PostedApr 24, 2020
Enrollment StartDec 3, 2018
Primary CompletionApr 7, 2023
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 6.2 years ago
Interventions
Itacitinibdrug
Novel and small molecule selective inhibitor of JAK1